Diagnostics

The reality of implementing an Alzheimer’s disease ‘blood test’ in clinical practice

Research needs: determining reliability and robustness of plasma markers in Alzheimer’s disease

Facilitation of dementia diagnosis across the world

Blood biomarkers for the differential diagnosis of Alzheimer’s disease in clinical practice

Decreased kidney function associated with increased plasma p-tau levels

Validating blood-based biomarker assays for use in Alzheimer’s disease clinical care

Assessing depressive symptoms in dementia screening

Why does tau-PET not detect the earliest stages of Alzheimer’s disease?

Alzheimer’s disease subtypes identified based on blood proteomics

Depressive symptom assessment can accurately detect cognitive decline

Access to Alzheimer’s disease diagnostic biomarkers in clinical routine

A future scenario: digital and blood biomarkers for Alzheimer’s disease diagnosis in primary care

Current and future role of tau-PET in dementia daily practice

Primary care digital screening tool for Alzheimer’s disease

Clinical robustness of CSF pTau/Aβ42 ratio for Alzheimer’s disease diagnosis

Mild behavioral impairment is associated with abnormal AD CSF biomarker profiles in MCI